MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V108.11.1967.1967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia

  2015cites this paper
• ENMD-2076 for hematological malignancies

  2012cites this paper
• From Discovery to Clinic: Aurora Kinase Inhibitors as Novel Treatments for Cancer

  2011cites this paper
• Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases

  2010cites this paper
• Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis

  2009cites this paper
• Aurora kinase inhibitors in preclinical and clinical testing

  2009cites this paper
• Miscreant myeloproliferative disorder stem cells

  2008cites this paper
• From palliation to epigenetic therapy in myelofibrosis.

  2008cites this paper
• New insights into the pathogenesis and treatment of chronic myeloproliferative disorders

  2008cites this paper
• Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

  2007cites this paper
• The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges.

  2007cites this paper
• Molecular characterization of acute myeloid leukemia and its impact on treatment

  2007cites this paper
• Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.

  2007cites this paper
• Emerging Role of Aurora Kinase Inhibitors in Chronic Myeloid Leukemia

  2007cites this paper
• New and Old Treatment Modalities in Primary Myelofibrosis

  2007cites this paper